Profile data is unavailable for this security.
About the company
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Company’s portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
- Revenue in SEK (TTM)0.00
- Net income in SEK-5.58m
- Incorporated1999
- Employees1.00
- LocationLidds ABVirdings Alle 32 BUPPSALA 754 50SwedenSWE
- Phone+46 42387427
- Fax+46 42387401
- Websitehttps://liddspharma.com/
More ▼
Mergers & acquisitions
| Acquired company | LIDDS:STO since announced | Transaction value |
|---|---|---|
| Proport Invest AB | -59.00% | 7.56m |
Data delayed at least 15 minutes, as of Feb 09 2026 22:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lidds AB | 0.00 | -5.58m | 6.82m | 1.00 | -- | 4.57 | -- | -- | -0.0409 | -0.0409 | 0.00 | 0.0109 | 0.00 | -- | -- | 0.00 | -99.68 | -64.76 | -119.64 | -76.72 | -- | -1,554.86 | -- | -2,637.08 | -- | -- | 0.00 | -- | -- | -- | 85.23 | -- | -65.39 | -- |
| PCI Biotech Holding ASA | 4.37m | -19.13m | 8.31m | 7.00 | -- | 0.7128 | -- | 1.90 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -8.42m | 12.52m | 2.00 | -- | 1.48 | -- | -- | -0.168 | -0.168 | 0.00 | 0.1314 | 0.00 | -- | -- | 0.00 | -78.98 | -78.82 | -83.99 | -92.78 | -- | -- | -- | -- | -- | -- | 0.0913 | -- | -- | -- | 47.69 | -- | -- | -- |
| Respiratorius AB (publ) | 0.00 | -7.12m | 12.64m | -- | -- | 0.3916 | -- | -- | -1.30 | -1.30 | 0.00 | 4.09 | 0.00 | -- | -- | -- | -21.57 | -- | -22.10 | -- | -- | -- | -- | -- | -- | -133.51 | 0.00 | -- | -- | -- | 3.36 | -- | -32.52 | -- |
| Fluicell AB | 2.68m | -9.86m | 12.98m | 11.00 | -- | 1.20 | -- | 4.84 | -7.18 | -7.18 | 1.95 | 7.86 | 0.1257 | -2.79 | 3.22 | 268,100.00 | -46.21 | -89.03 | -62.52 | -133.15 | 428.87 | 86.83 | -367.74 | -656.39 | 0.6057 | -- | 0.00 | -- | -44.31 | -5.66 | 41.59 | -- | 33.86 | -- |
| Gabather AB | 0.00 | -4.65m | 14.75m | 2.00 | -- | -- | -- | -- | -0.0384 | -0.0384 | 0.00 | -0.0111 | 0.00 | -- | -- | 0.00 | -209.07 | -67.13 | -- | -90.59 | -- | -- | -- | -- | -- | -76.57 | -- | -- | -- | -- | 17.84 | -- | -- | -- |
| Novakand Pharma AB | 0.00 | -51.90m | 15.58m | 5.00 | -- | 0.778 | -- | -- | -0.4283 | -0.4283 | 0.00 | 0.1653 | 0.00 | -- | -- | 0.00 | -103.07 | -54.11 | -112.87 | -63.47 | -- | 70.00 | -- | -275,694.40 | -- | -- | 0.00 | -- | -- | -- | 31.32 | -- | -- | -- |
| ATTANA AB | 4.10m | -12.78m | 20.64m | 6.00 | -- | 0.6084 | -- | 5.03 | -0.0154 | -0.0154 | 0.0047 | 0.0132 | 0.1425 | -0.7611 | 1.02 | 656,600.00 | -44.37 | -37.91 | -61.34 | -48.09 | 161.16 | 189.23 | -311.34 | -305.50 | 0.6079 | -3.79 | 0.1315 | -- | -18.77 | -8.69 | 7.33 | -- | 8.51 | -- |
| Lumito AB (publ) | 81.51k | -48.06m | 28.56m | 8.00 | -- | 0.2061 | -- | 350.38 | -20.16 | -20.16 | 0.0253 | 40.27 | 0.0008 | -0.4224 | 0.0791 | 6,792.50 | -47.58 | -24.12 | -62.09 | -26.46 | 546.44 | -- | -58,966.97 | -138,894.00 | 0.2668 | -22.92 | 0.1994 | -- | -- | -- | -61.08 | -- | -30.66 | -- |
| Aptahem AB | 0.00 | -7.43m | 31.57m | -- | -- | 0.2568 | -- | -- | -0.6711 | -0.6711 | 0.00 | 3.77 | 0.00 | -- | -- | -- | -11.21 | -30.70 | -11.57 | -34.24 | -- | -- | -- | -- | -- | -44.15 | 0.00 | -- | -- | -- | 22.90 | -- | 88.99 | -- |
| Peptonic Medical AB | 15.69m | -48.98m | 33.61m | 3.00 | -- | 0.481 | -- | 2.14 | -0.0068 | -0.0068 | 0.002 | 0.0037 | 0.1994 | 0.6491 | 3.47 | 2,242,000.00 | -62.23 | -52.80 | -86.90 | -72.84 | 67.85 | 54.48 | -312.10 | -141.78 | 0.2747 | -26.44 | 0.2863 | -- | -27.55 | 43.57 | -40.95 | -- | 11.04 | -- |
| Strategic Partners A/S | 0.00 | -4.74m | 33.95m | 1.00 | -- | 1.32 | -- | -- | -83.43 | -83.43 | 0.00 | 433.01 | 0.00 | -- | -- | 0.00 | -18.16 | -66.13 | -19.52 | -94.41 | -- | -- | -- | -- | -- | -69.91 | 0.00 | -- | -- | -- | 98.86 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -17.94m | 34.06m | 2.00 | -- | 2.34 | -- | -- | -0.1796 | -0.1796 | 0.00 | 0.1196 | 0.00 | -- | -- | 0.00 | -137.62 | -123.65 | -167.64 | -208.97 | -- | -- | -- | -- | -- | -63.99 | 0.00 | -- | -- | -- | 13.14 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to Lidds AB's reporting currency: Swedish Krona SEK
